Table 13.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1992 to 2001

Recipients with Heart-Lung Transplants

		Year of Transplant
		1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Transplants		48	60	71	69	39	61	47	51	48	27
Tx with Antirejection Treatments		20	25	29	35	9	13	25	18	16	4
Antibodies	Category Usage	10.0%	20.0%	17.2%	8.6%	11.1%	15.4%	20.0%	5.6%	18.8%	0.0%
	ALG	0.0%	0.0%	3.4%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG	0.0%	12.0%	6.9%	5.7%	11.1%	7.7%	12.0%	0.0%	6.3%	0.0%
	NRATG/NRATS	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	4.0%	0.0%	0.0%	0.0%
	OKT3	10.0%	12.0%	6.9%	2.9%	0.0%	7.7%	0.0%	0.0%	0.0%	0.0%
	Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	4.0%	5.6%	0.0%	0.0%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	12.5%	0.0%
Corticosteroids	Category Usage	95.0%	80.0%	86.2%	100.0%	100.0%	100.0%	92.0%	94.4%	93.8%	100.0%
	Steroids	95.0%	80.0%	86.2%	100.0%	100.0%	100.0%	92.0%	94.4%	93.8%	100.0%

Source: OPTN/SRTR Data as of August 1, 2003.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.